Cargando…
Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies
BACKGROUND: Patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) report difficulty with sleep. METHODS: We examined the effect of omalizumab on sleep-related outcomes during 3–6 months omalizumab or placebo treatment and a 16-week follow-up period within three Phase III double-blind rand...
Autores principales: | Gimenéz-Arnau, Ana M., Spector, Sheldon, Antonova, Evgeniya, Trzaskoma, Benjamin, Rosén, Karin, Omachi, Theodore A., Stull, Donald, Balp, Maria-Magdalena, Murphy, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989527/ https://www.ncbi.nlm.nih.gov/pubmed/27540466 http://dx.doi.org/10.1186/s13601-016-0120-0 |
Ejemplares similares
-
Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria
por: Graham, Jonathan, et al.
Publicado: (2016) -
Omalizumab substantially improves dermatology‐related quality of life in patients with chronic spontaneous urticaria
por: Finlay, A.Y., et al.
Publicado: (2017) -
Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H(1) Antihistamines: A Randomized, Placebo-Controlled Study
por: Saini, Sarbjit S, et al.
Publicado: (2015) -
Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence
por: Metz, Martin, et al.
Publicado: (2020) -
EQ-5D Utilities in Chronic Spontaneous/Idiopathic Urticaria
por: Hawe, Emma, et al.
Publicado: (2016)